Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for ml min m. hamal
Your search for Ma’mon M. Hatmal retrieved no results
Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial.
Birudaraju D, Cherukuri L, Kinninger A, Dahal S, Lakshmanan S, Rezvanizadeh V, Ghanem AK, Flores F, Hamal S, Pozon RG, Adudodla N, Tayek JA, Roy SK, Budoff MJ. Birudaraju D, et al. J Diabetes Complications. 2021 Mar;35(3):107840. doi: 10.1016/j.jdiacomp.2020.107840. Epub 2020 Dec 31. J Diabetes Complications. 2021. PMID: 33419635 Clinical Trial.
Of interest, 14 persons with diabetes with normal coronaries (no calcification) were significantly more likely to be females (21% vs 62%), have higher glomerular filtration rate (106.5 19.4 vs 89.9 22.6 mL/min/1.73m(2); p= 0.006), and younger (53.4 9.0 vs 56.4 8.4 yrs.; p= …
Of interest, 14 persons with diabetes with normal coronaries (no calcification) were significantly more likely to be females (21% vs 62%), h …
Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.
Chaftari AM, Hachem R, Jordan M, Garoge K, Al Hamal Z, El Zakhem A, Viola GM, Granwehr B, Mulanovich V, Gagel A, Reitzel R, Yousif A, Jiang Y, Raad I. Chaftari AM, et al. Antimicrob Agents Chemother. 2015 Oct 19;60(1):239-44. doi: 10.1128/AAC.00617-15. Print 2016 Jan. Antimicrob Agents Chemother. 2015. PMID: 26482312 Free PMC article. Clinical Trial.
Patients with baseline creatinine clearance (CLCR) values of >50 ml/min received 10 mg/kg/day of telavancin, and those with CLCR values between 30 and 49 ml/min received 7.5 mg/kg/day. ...
Patients with baseline creatinine clearance (CLCR) values of >50 ml/min received 10 mg/kg/day of telavancin, and those with CLCR v …